Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Array BioPharma’s pain drug meets Phase II study endpoints
ARRY-797 has achieved its primary and secondary endpoints for analgesic effect and was well-tolerated in this phase II clinical trial. The analgesic effect of 400mg of ARRY-797 administered
ARRY-797 has achieved its primary and secondary endpoints for analgesic effect and was well-tolerated in this phase II clinical trial. The analgesic effect of 400mg of ARRY-797 administered
In these roles, Mr Holtz will be responsible for oversight of the controller’s group, treasury, risk management and information technology reporting to Thomas Gardner, chairman and CEO of
Effective immediately, the scientific research communities in Hong Kong, Shanghai, Beijing and Guangzhou now have access to this important cell analysis technology. Cheung To, chairman of Gene Company,
The product is available in bottles of 100 tablets for all strengths as well as unit dose blisters for the 50mg strength and is available for immediate shipment
Sumatriptan injection is the generic form of GlaxoSmithKline’s Imitrex injection, which is currently selling on the market and is indicated for the acute treatment of migraine attacks with
The data also showed improved surgical incision wound healing in an in vivo porcine model compared to traditional electrosurgery. The company has filed a 510(k) pre-market notification with
Through the application of the advancing technology of pattern recognition, this new SVM-based system is intended to further improve the sensitivity of the Pap test and augment the
The higher doses of PF-03187207 demonstrated a clinically significant reduction in diurnal intraocular pressure (IOP) from baseline and the highest dose showed consistently more IOP lowering than Xalatan
Results of this first head-to-head trial of Menveo compared to Menactra, show that adolescents who were immunized with Menveo generated higher levels of antibodies against all four serogroups.
Utilizing enzyme-based technology developed at Thermo Fisher Scientific’s Milwaukee, Wisconsin, molecular bioreagents facility, Dalton will produce poly-inosine (Poly-I) and poly-cytosine (Poly-C) in accordance with cGMP regulations. Poly-I and